Elucidata was founded in 2015 with the mandate to transform the way biological data is used to drive decisions in R&D labs in both academia and industry. Polly, an end-to-end, vendor-neutral, cloud-based platform standardizes and streamlines the data analysis workflows for -omics experiments. Elucidata's long-term goal is to utilize its data analysis platform to integrate different types of -omics data in order to understand cellular phenotypes and accelerate the pace of drug discovery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/18/18 | $1,700,000 |
Hyperplane Venture Capital | undisclosed | |
| 02/04/21 | $5,000,000 | Pre-Series A |
Hyperplane Venture Capital IvyCap Ventures | undisclosed |
